hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06269445, orgStudyIdInfo id: 2023-942-01, briefTitle: The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2026-02-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Sir Run Run Shaw Hospital, class: OTHER, descriptionModule briefSummary: To evaluate the efficacy and safety of the combination regimen of Icaritin with bevacizumab + FOLFIRI in patients with liver metastases from advanced colorectal cancer., conditionsModule conditions: Colorectal Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Icaritin Combined With Bevacizumab and FOLFIRI, outcomesModule primaryOutcomes measure: Progression-free survival(PFS), secondaryOutcomes measure: Objective remission rate (ORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Duration of ongoing remission (DOR), secondaryOutcomes measure: TRAEs, secondaryOutcomes measure: Quality of life of the patients, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310000, country: China, contacts name: Fei Wang, role: CONTACT, phone: 13732236150, email: 21418531@zju.edu.cn, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06269432, orgStudyIdInfo id: 2023YFS0042, briefTitle: Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Acute Ischemic STROKE（PATH-STROKE）, acronym: PATH-STROKE, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Sichuan Provincial People's Hospital, class: OTHER, descriptionModule briefSummary: Objectives of Study:To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic cerebral infarction under the guidance of platelet aggregation function., conditionsModule conditions: Ischemic Stroke, conditions: Antiplatelet Drug, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 3524, type: ESTIMATED, armsInterventionsModule interventions name: Precision Antiplatelet Therapy Trial Group, interventions name: Traditional Antiplatelet Therapy Control Group, outcomesModule primaryOutcomes measure: 3-month major ischemic events and major bleeding events, secondaryOutcomes measure: disability, secondaryOutcomes measure: Cardiovascular or cerebrovascular mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sichuan Provincial People's Hospital, status: RECRUITING, city: Chengdu, state: Sichuan, zip: 610072, country: China, contacts name: Jie Yang, doctor, role: CONTACT, phone: +86 13678130516, email: yangjie1126@163.com, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06269393, orgStudyIdInfo id: CIBI311Y101, briefTitle: A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2026-02-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Peking University People's Hospital, class: OTHER, descriptionModule briefSummary: This is an exploratory study of the efficacy and safety of IBI311, a modified anti-IGF-1R antibody, in patients with steroid-resistant, thyroid associated ophthalmopathy (TAO). This study includes two stages. Stage I is a single-center, single-arm, open-label clinical study designed to evaluate the safety and tolerability of IBI311 in subjects with TAO. Approximately 10 subjects meeting the study eligibility criteria will be enrolled. Stage II is a single-center, randomized, double-masked, placebo-controlled clinical trial designed to evaluate the efficacy and safety of IBI311 in subjects with steroid-resistant TAO. Approximately 54 subjects meeting the study eligibility criteria will be randomly assigned to IBI311 or placebo on day 1 (D1) in a 2:1 ratio stratified by disease activity., conditionsModule conditions: Thyroid Associated Ophthalmopathy, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Placebo, interventions name: IBI311, outcomesModule primaryOutcomes measure: The proptosis responder rate (defined as percentage of subjects with a ≥ 2mm reduction from baseline in proptosis in the study eye, without deterioration [≥ 2 mm increase] of proptosis in the non-study eye) of the study eye., secondaryOutcomes measure: Overall responder rate in proptosis of the study eye., secondaryOutcomes measure: Percentage of subjects with a CAS value of 0 or 1, secondaryOutcomes measure: Diplopia responder rate (defined as percentage of subjects with a ≥ 1-grade improvement in diplopia), otherOutcomes measure: Safety and tolerability of intravenous IBI311 in subjects with TAO, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University People's Hospital, city: Beijing, state: Beijing, zip: 100034, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06269380, orgStudyIdInfo id: 30.01.2024-4274, briefTitle: Evaluation of Antral Biopsies Obtained in Normal Esophagogastroduodenoscopy, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-02-13, primaryCompletionDateStruct date: 2024-02-20, completionDateStruct date: 2024-02-21, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Sisli Hamidiye Etfal Training and Research Hospital, class: OTHER, descriptionModule briefSummary: Esophagogastroduodenoscopy (EGD) is commonly performed in patients presenting with abdominal pain and dyspeptic symptoms, serving as a valuable diagnostic and therapeutic tool. While various methods are available for biopsy sampling when mucosal pathology is observed during EGD, the practice of obtaining biopsies from endoscopically normal mucosa remains controversial. Although there is literature suggesting that routine biopsies from the antrum and duodenum for surveillance purposes increase costs, pathological findings can sometimes be detected in areas that appear normal on mucosal examination, leading to potential changes in treatment approach if biopsies are obtained.In this study, a retrospective evaluation of the prevalence of various pathologies detected in biopsies obtained from endoscopically normal mucosa in patients who underwent EGD was reported as normal., conditionsModule conditions: Gastritis H Pylori, conditions: Gastritis Chronic, conditions: Intestinal Metaplasia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The biopsies obtained from patients who underwent esophagogastroduodenoscopy and were found to have normal endoscopic findings will be evaluated. The histopathological findings and their frequencies in these biopsies will be examined to assess the necessity of routine biopsy during esophagogastroduodenoscopy., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 671, type: ACTUAL, armsInterventionsModule interventions name: Esophagogastroduodenoscopy, interventions name: Endoscopic biopsy sampling, outcomesModule primaryOutcomes measure: Rate of abnormal histopathologic findings, secondaryOutcomes measure: Rate of intestinal metaplasia, secondaryOutcomes measure: Rates of gastritis severity and activity, secondaryOutcomes measure: Rate of Helicobacter Pylori positivity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 95 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sisli Hamidiye Etfal Research and Training Hospital, city: Istanbul, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06269367, orgStudyIdInfo id: HUM00226149, secondaryIdInfos id: 1R41HD111289-01, type: NIH, link: https://reporter.nih.gov/quickSearch/1R41HD111289-01, briefTitle: NewGait: A Low-Cost Rehabilitation System to Improve Post-Stroke Gait (Biomechanical Adaptations), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University of Michigan, class: OTHER, collaborators name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), descriptionModule briefSummary: An affordable and easy to use gait-assistive device for stroke survivors to use at home is yet to be developed. This study is intended to modify the current design of the NewGait device to specifically work for stroke survivors based on feedback from patients and clinicians. Consequently, conducting a short-term biomechanical gait study is planned to determine the usability and functionality of the NewGait device compared to other comparative devices., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Participants will be randomly assigned to the two device interventions but will receive both interventions., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: NewGait, interventions name: Control wearable limb orthotic device, outcomesModule primaryOutcomes measure: Gait speed, primaryOutcomes measure: Ankle Muscle Activation, secondaryOutcomes measure: Changes in paretic leg propulsive force, otherOutcomes measure: Changes in paretic leg loading (i.e., vertical ground reaction force), otherOutcomes measure: Changes in other lower extremity muscle activation, otherOutcomes measure: Muscle Coordination, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Physical Medicine & Rehabilitation 325 E Eisenhower Pkwy Suite 3011, status: RECRUITING, city: Ann Arbor, state: Michigan, zip: 48108, country: United States, contacts name: Chanramouli Krishnan, PT, PhD, role: CONTACT, phone: 734-936-4031, email: mouli@umich.edu, geoPoint lat: 42.27756, lon: -83.74088, hasResults: False
protocolSection identificationModule nctId: NCT06269354, orgStudyIdInfo id: 20231121-71479, briefTitle: Multi-center Study on Comprehensive Diagnosis and Treatment of Lower Limb Bone Defect Based on Three-dimensional Printing Technology, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-01, primaryCompletionDateStruct date: 2026-06-01, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Peking University Third Hospital, class: OTHER, descriptionModule briefSummary: The clinical diagnosis and treatment of lower limb bone defect is a difficult problem in orthopedics. The traditional treatment has the shortcomings of long treatment period, no weight bearing in the early stage of the limb, weak mechanical strength, many complications, and difficulty in repairing deformed and large segment bone defects around the joint. The Orthopedics Department of Peking University Third Hospital, the lead unit of this study, developed the TCBridge system based on three-dimensional (3D) printing technology in the early stage, which is the first approved 3D printing lower limb long bone defect repair system in China. The system can achieve personalized and accurate repair of lower limb bone defects, and ensure patients to carry out limb weight and functional exercise safely in the early stage after surgery. On this basis, this study will establish a multi-center clinical case cohort to achieve accurate comprehensive diagnosis and treatment of lower limb bone defects, benefiting patients and contributing to society., conditionsModule conditions: Bone Defects, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: 3D printed prostheses, outcomesModule primaryOutcomes measure: Evaluation of implant stability, new bone growth- limb length, primaryOutcomes measure: Evaluation of bone healing, secondaryOutcomes measure: Pain assessment, secondaryOutcomes measure: Evaluation of life quality and health status., secondaryOutcomes measure: Evaluation of knee function, secondaryOutcomes measure: Evaluation of hip function, secondaryOutcomes measure: Evaluation of ankle function, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University Third Hospital, status: RECRUITING, city: Beijing, state: Haidian, country: China, contacts name: Bingchuan Liu, role: CONTACT, phone: +86 18310188678, email: liubc@bjmu.edu.cn, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06269341, orgStudyIdInfo id: SCCH-TS2208, briefTitle: Outcomes of Smoker and Drinker With Esophageal Squamous Cell Carcinoma After Esophagectomy, acronym: OSinEC, statusModule overallStatus: RECRUITING, startDateStruct date: 2010-02-01, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-08-30, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Sichuan Cancer Hospital and Research Institute, class: OTHER, descriptionModule briefSummary: Our study demonstrates that patients who did not consume alcohol or smoke had a significant advantage in overall survival (OS) after undergoing esophagectomy. Furthermore, our findings indicate that there was no statistically significant difference in OS between patients with a history of both smoking and drinking, and those who only smoked or drank, conditionsModule conditions: Outcomes of Smoker and Drinker After Esophagectomy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 2957, type: ESTIMATED, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: Overall Survival, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sichuan Cancer Hospital and Research Institute, status: RECRUITING, city: Chengdu, state: Sichuan, zip: 610041, country: China, contacts name: Lin Peng, M.D., role: CONTACT, phone: +8618908190013, email: penglinms@126.com, contacts name: Wenwu He, M.D., role: CONTACT, phone: +8613350055340, email: wenwu_he@126.com, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06269328, orgStudyIdInfo id: 2011-KAEK-26/463, briefTitle: Measuring Sleep Quality In Patients That Posterior Spinal Instrumentatıon Plannıng, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-07-01, primaryCompletionDateStruct date: 2023-09-01, completionDateStruct date: 2024-01-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Uludag University, class: OTHER, descriptionModule briefSummary: Postoperative sleep disorders have serious problems with cognition, pain perception, sustained circadian rhythm, psychomotor function, metabolic function, catabolic responses, and continuity. The relationship between general anesthesia and sleep disturbances following surgery is still unclear. Since the risk of sleep disorders after surgery is high, it is important to determine the efficiency of the interval with automatic sleep disorders. By evaluating how major orthopedic surgery and general anesthesia applied to posterior spinal instrumentation divides sleep quality, risk management allows determining the factors involved in the peroperative period and thus facilitating surgical results and patient comfort., conditionsModule conditions: Sleep Disorder, conditions: Sleep, Inadequate, conditions: Total ıntravenous Anesthesia, conditions: Inhalation Anesthesia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 39, type: ACTUAL, armsInterventionsModule interventions name: Total ıntravenous anesthesia with propofol and remifentanil for anesthetic maintenance, interventions name: Inhalation anesthesia with sevoflurane for anesthetic maintenance, outcomesModule primaryOutcomes measure: Subjective sleep quality (evaluated by PIRS-20 (Pitssburg Insomnia Rating Scale), secondaryOutcomes measure: Subjective anxiety level, secondaryOutcomes measure: Subjective pain level, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Elifgül Ulutaş, city: Bursa, state: Nilüfer, zip: 16240, country: Turkey, geoPoint lat: 40.19559, lon: 29.06013, hasResults: False
protocolSection identificationModule nctId: NCT06269302, orgStudyIdInfo id: 2, briefTitle: Comparison of the Effect of Warfarin and Direct Oral Anticoagulants, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-01, primaryCompletionDateStruct date: 2022-12-31, completionDateStruct date: 2022-12-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Samsun Education and Research Hospital, class: OTHER, descriptionModule briefSummary: In this study, it was aimed to compare the frequency of new oral anticoagulants and warfarin usage, and to reveal the rates of recurrent upper gastrointestinal bleeding among patients who applied to our hospital with upper gastrointestinal bleeding, conditionsModule conditions: Anticoagulants and Bleeding Disorders, conditions: Gastrointestinal Hemorrhage, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 346, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Change in the incidence of recurrent bleeding, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Samsun Education and Research Hospital, city: Samsun, state: İlkadım, country: Turkey, geoPoint lat: 41.27976, lon: 36.3361, hasResults: False
protocolSection identificationModule nctId: NCT06269276, orgStudyIdInfo id: CAVCU, briefTitle: Caregiver Contribution to Self-Care in Ostomy Patient Index: Turkish Validity and Reliability Study, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-09-20, primaryCompletionDateStruct date: 2021-01-15, completionDateStruct date: 2021-01-15, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Namik Kemal University, class: OTHER, descriptionModule briefSummary: This study was conducted to evaluate the Turkish validity and reliability of the Caregiver Contribution to Self-Care in Ostomy Patient Index, to evaluate the relatives of patients with stoma who contribute to their self-care in Turkish society, and to contribute to the nursing literature of the measurement tool.This methodological type of research was carried out between September 2020 and January 2021 in a state and a university hospital in Tekirdağ. The research sample consisted of 223 individuals who contributed to the self-care of individuals with colostomy, ileostomy and urostomy who applied for outpatient control. In the analysis of the data, descriptive statistics, language and content validity, confirmatory factor analysis, item analysis, internal consistency and test-retest methods were used.At the end of the study, it was determined that the scale was suitable for Turkish society and was valid and reliable in Turkish., conditionsModule conditions: Stoma Colostomy, conditions: Stoma Ileostomy, conditions: Caregiver, conditions: Self Care, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 223, type: ACTUAL, armsInterventionsModule interventions name: Caregiver Contribution to Self-Care in Ostomy Patient Index, outcomesModule primaryOutcomes measure: Caregiver Contribution to Self-Care in Ostomy Patient Index, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tekirdag Namık Kemal University, city: Tekirdag, state: Suleymanpasa, zip: 59000, country: Turkey, geoPoint lat: 40.9781, lon: 27.51101, hasResults: False